גאלבוס 50 מ"ג

Country: Iżrael

Lingwa: Ebrajk

Sors: Ministry of Health

Ingredjent attiv:

VILDAGLIPTIN 50 MG

Disponibbli minn:

NOVARTIS PHARMA SERVICES AG

Kodiċi ATC:

A10BH02

Għamla farmaċewtika:

TABLETS

Rotta amministrattiva:

PER OS

Manifatturat minn:

NOVARTIS PHARMA STEIN AG, SWITZERLAND

Grupp terapewtiku:

VILDAGLIPTIN

Indikazzjonijiet terapewtiċi:

Galvus is indicated as an adjunct to diet and exercise in patients with type 2 diabetes mellitus• As monotherapy, if diet and exercise are not sufficient, or• In combination with metformin, or a sulfonylurea if treatment with these oral antidiabetics does not offer sufficient control of blood glucose.As triple oral therapy in combination with• a sulphonylurea and metformin when diet and exercise plus dual therapy with these agents do not provide adequate glycaemic control. Galvus is also indicated for use in combination with insulin (with or without metformin) when diet and exercise plus a stable dose of insulin do not provide adequate glycaemic control.

Data ta 'l-awtorizzazzjoni:

2013-11-01